1-3 of 3
Yuchen Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study

Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Jian Zhang, Ai-min Hui, Zhuli Wu, Yuchen Yang, Han Zhao, Yiqian Jiang, Lu Si
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT519.
DOI: https://doi.org/10.1158/1538-7445.AM2022-CT519
Published: 15 June 2022
View article
Journal Articles

Single-Cell Analysis Unveils the Role of the Tumor Immune Microenvironment and Notch Signaling in Dormant Minimal Residual Disease

Mahnaz Janghorban, Yuchen Yang, Na Zhao, Clark Hamor, Tuan M. Nguyen, Xiang H.-F. Zhang, Jeffrey M. Rosen
Journal: Cancer Research
Cancer Res (2022) 82 (5): 885–899.
DOI: https://doi.org/10.1158/0008-5472.CAN-21-1230
Published: 03 March 2022
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract CT117: Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2- advanced breast cancer (ABC)

Jian Zhang, Xiaojia Wang, Xian Wang, Aimin Hui, Zhuli Wu, Ling Tian, Changjiang Xu, Yuchen Yang, Wenjing Zhang, Xichun Hu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT117.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT117
Published: 01 July 2021
View article